Suman Kambhampati, MD
There are many molecular subgroups in acute myeloid leukemia (AML) that reflect the evolution of the disease and aid in prognostication, according to Suman Kambhampati, MD. In recent years, certain mutations have provided clues as to how to optimally treat patients.
-ITD, and new agents on the horizon for the treatment of patients with AML.
Impact of NGS
One of the most discussed AML abstracts at the 2018 ASCO Annual Meeting, according to Kambhampati, investigated the impact of NGS on treatment selection for patients with AML.1
This retrospective analysis looked at NGS of more than 1400 patients who were treated over a decade, beginning with a 53-gene panel, and followed by a 28-gene panel.
... to read the full story